PMID- 34424127
OWN - NLM
STAT- MEDLINE
DCOM- 20220119
LR  - 20220430
IS  - 1744-7674 (Electronic)
IS  - 1354-3776 (Linking)
VI  - 32
IP  - 1
DP  - 2022 Jan
TI  - Why do few drug delivery systems to combat neglected tropical diseases reach the 
      market? An analysis from the technology's stages.
PG  - 89-114
LID - 10.1080/13543776.2021.1970746 [doi]
AB  - INTRODUCTION: Many drugs used to combat schistosomiasis, Chagas disease, and 
      leishmaniasis (SCL) have clinical limitations such as: high toxicity to the 
      liver, kidneys and spleen; reproductive, gastrointestinal, and heart disorders; 
      teratogenicity. In this sense, drug delivery systems (DDSs) have been described 
      in the literature as a viable option for overcoming the limitations of these 
      drugs. An analysis of the level of development (TRL) of patents can help in 
      determine the steps that must be taken for promising technologies to reach the 
      market. AREAS COVERED: This study aimed to analyze the stage of development of 
      DDSs for the treatment of SCL described in patents. In addition, we try to 
      understand the main reasons why many DDSs do not reach the market. In this study, 
      we examined DDSs for drugs indicated by WHO and treatment of SCL, by performing a 
      search for patents. EXPERT OPINION: In this present work we provide arguments 
      that support the hypothesis that there is a lack of integration between academia 
      and industry to finance and continue research, especially the development of 
      clinical studies. We cite the translational research consortia as the potential 
      alternative for developing DDSs to combat NTDs.
FAU - Profiro de Oliveira, Jabson Herber
AU  - Profiro de Oliveira JH
AUID- ORCID: 0000-0003-0356-8083
AD  - Department of Pharmacy, Federal University of Pernambuco, Recife, 
      Recife-Pernambuco.
FAU - Arruda, Igor Eduardo Silva
AU  - Arruda IES
AUID- ORCID: 0000-0002-6557-4748
AD  - Department of Pharmacy, Federal University of Pernambuco, Recife, 
      Recife-Pernambuco.
FAU - Izak Ribeiro de Araujo, Jose
AU  - Izak Ribeiro de Araujo J
AUID- ORCID: 0000-0002-0675-5485
AD  - Department of Pharmacy, Federal University of Pernambuco, Recife, 
      Recife-Pernambuco.
FAU - Chaves, Luise Lopes
AU  - Chaves LL
AUID- ORCID: 0000-0002-1197-7306
AD  - Department of Pharmacy, Federal University of Pernambuco, Recife, 
      Recife-Pernambuco.
FAU - de La Rocca Soares, Monica Felts
AU  - de La Rocca Soares MF
AUID- ORCID: 0000-0002-4873-915X
AD  - Department of Pharmacy, Federal University of Pernambuco, Recife, 
      Recife-Pernambuco.
FAU - Soares-Sobrinho, Jose Lamartine
AU  - Soares-Sobrinho JL
AUID- ORCID: 0000-0002-3280-0294
AD  - Department of Pharmacy, Federal University of Pernambuco, Recife, 
      Recife-Pernambuco.
LA  - eng
PT  - Journal Article
DEP - 20210907
PL  - England
TA  - Expert Opin Ther Pat
JT  - Expert opinion on therapeutic patents
JID - 9516419
SB  - IM
MH  - Drug Delivery Systems
MH  - Humans
MH  - Neglected Diseases/drug therapy
MH  - *Patents as Topic
MH  - *Schistosomiasis/drug therapy
MH  - Technology
OTO - NOTNLM
OT  - Drug delivery system
OT  - nanotechnology
OT  - neglected tropical disease
OT  - technology readiness levels
EDAT- 2021/08/24 06:00
MHDA- 2022/01/20 06:00
CRDT- 2021/08/23 12:17
PHST- 2021/08/24 06:00 [pubmed]
PHST- 2022/01/20 06:00 [medline]
PHST- 2021/08/23 12:17 [entrez]
AID - 10.1080/13543776.2021.1970746 [doi]
PST - ppublish
SO  - Expert Opin Ther Pat. 2022 Jan;32(1):89-114. doi: 10.1080/13543776.2021.1970746. 
      Epub 2021 Sep 7.